The future is for

fighting the spread with rapid, at-home tests

accurate, inexpensive, and easy-to-use.

those who decrease the public health threat.

augmenting human capabilities with AI.

computer vision as a core technology in medicine.

distributed medical diagnoses.

Read our September 16 press release here
       
Our Mission
Learn More
   

Who we’re working with

How it works

   

Sound interesting?

Contact Us

Still have questions?

Why is an at-home rapid antigen test necessary?

The Gauss-Cellex announcement comes amidst a growing consensus among public health officials and business leaders that a widely-accessible rapid antigen testing solution is needed to decrease the public health threat from COVID-19 and mitigate the pandemic’s economic impact until a vaccine is widely available. A rapid, reliable, inexpensive and consumer-friendly at-home antigen test would significantly reduce virus transmission, particularly by asymptomatic and pre-symptomatic patients, while enabling people with negative results to engage in their day-to-day activities – from going to work, going to school, shopping, visiting a relative or vacationing –with a significantly lower risk of transmission. However, widespread use of rapid tests is currently limited by the need for trained clinical operators or specialized laboratory equipment to ensure that tests are performed and interpreted accurately.see more

How does the test work?

To perform at-home testing, users follow step-by-step video instructions in the app to correctly collect a nasal swab sample and perform the rapid antigen test. Within 15 minutes, the app prompts the user to scan their rapid test with their smartphone and then processes the image with an end-to-end neural network architecture optimized for the Cellex assay. The app informs the user if the test result is negative or positive for SARS-CoV-2 antigens within seconds. Gauss’s patent-pending, AI-driven assay reading technology overcomes the limit of detection of the untrained human eye and can also minimize inter-reader variability routinely seen in interpreting antigen test results. Put together, the solution will deliver fast and reliable results on an encrypted, HIPAA-compliant, consumer-friendly app.see more

What equipment is required in order to perform the test at home?

The test kit includes all the materials necessary to perform the test and the free smartphone app allows users to read the test, so no additional instrument or equipment is necessary.

How well does the test perform?

Cellex, which was the first company to receive an FDA Emergency Use Authorization for rapid COVID-19 antibody testing, is now in advanced clinical trials with a rapid antigen test that targets the nucleocapsid (N) protein on the SARS-CoV-2 virus and has demonstrated nearly 90% sensitivity and 100% specificity in early trials. When paired with a newly developed, AI-powered application from Gauss that enables non-expert users to perform and interpret the test with an iPhone or Android phone, its use can be expanded to aid in the rapid diagnosis of SARS-CoV-2 infections in both at-home and point-of-care settings.see more

How long does it take to obtain results from the test?

Users will be able to scan their test with their smartphone 15 minutes after taking the nasal swab sample and activating the test. The app will then indicate the test result within seconds.

When will the test be available?

The test will require US FDA Emergency Use Authorization (EUA), which Gauss hopes will be authorized sometime this fall. The Gauss app is available on the Apple App Store and is already being used by research teams at large academic medical centers to power large-scale, at-home research studies on COVID-19. see more

How do I obtain a test?

The Gauss-Cellex at-home rapid antigen test will be made available through distribution partners as well as directly from Gauss. Please stay tuned for more information on how to order the test following FDA EUA.

How do I learn more about becoming a channel partner with Gauss?

Please send us an indication of interest by submitting your email and a message below, and we’ll be happy to reach out and discuss in greater detail. You can also email us directly at partners@gauss.com.see more

How do I learn more about acquiring the test for use within my organization?

Please send us an indication of interest by submitting your email and a message below, and we’ll be happy to reach out and discuss in greater detail. You can also email us directly at enterprise@gauss.com.see more